Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: dbuki who wrote (981)	5/27/2003 7:51:25 PM
From: SemiBull	Respond to of 1139

ICOS Corporation Files Shelf Registration Statement Tuesday May 27, 4:50 pm ET BOTHELL, Wash.--(BUSINESS WIRE)--May 27, 2003--ICOS Corporation (Nasdaq:ICOS - News) announced today that it has filed a universal shelf registration statement on Form S-3, with the Securities and Exchange Commission, which, when declared effective, will permit ICOS, from time to time, to offer and sell common stock, par value $0.01 per share, debt securities and convertible debt securities, up to a total value of $150,000,000. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, psoriasis and other inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in ICOS' latest Annual Report on Form 10-K and its other SEC filings. -------------------------------------------------------------------------------- Contact: ICOS Corporation Lacy Fitzpatrick, 425/415-2207 -------------------------------------------------------------------------------- Source: ICOS Corporation